Exploratory clinical and immunological changes following Tixagevimab/Cilgavimab administration in immunodeficient patients with SARS-CoV-2-associated ME/CFS and persistent circulating spike protein.
Seidel, Maximilian, Anft, Moritz, Wiemers, Lea et al.·Immunology letters·2026
Researchers gave a monoclonal antibody treatment (Tixagevimab/Cilgavimab) to nine immunodeficient patients with long COVID and ME/CFS-like symptoms who had detectable coronavirus spike protein in their blood. After 30 days, one immune marker (β1-adrenergic receptor autoantibody) showed a modest decrease, but spike protein levels and symptom outcomes did not change significantly as a group. These are very preliminary findings from a small study without a control group, and the authors emphasise that efficacy remains uncertain.